

EXPERIMENTAL MODEL FOR TREATMENT OF EXTENDED SPECTRUM BETALACTAMASE PRODUCING-*KLEBSIELLA PNEUMONIAE*

Modelo experimental de tratamento de sepse por *Klebsiella pneumoniae* produtora de betalactamase de amplo espectro

Paula Virginia Michelon **TOLEDO**^{1,2,6}, Felipe Francisco **TUON**^{1,3,6}, Larissa **BAIL**⁴,
Francine **MANENTE**⁴, Polliane **ARRUDA**¹, Ayrton Alves **ARANHA-JUNIOR**^{1,5}

From the ¹Departamento de Medicina, Universidade Estadual de Ponta Grossa, Ponta Grossa, PR; ²Departamento de Medicina, Pontifícia Universidade Católica do Paraná, Curitiba, PR; ³Departamento de Saúde Comunitária, Universidade Federal do Paraná, Curitiba, PR; ⁴Departamento de Farmácia e Bioquímica, Universidade Estadual de Ponta Grossa, Ponta Grossa; ⁵Programa de Pós-graduação em Clínica Cirúrgica, Universidade Federal do Paraná, Curitiba; ⁶Programa de Pós-graduação em Medicina Interna, Universidade Federal do Paraná, Curitiba, PR; ⁷Department of Medicine, State University of Ponta Grossa, Ponta Grossa, PR; ⁸Department of Medicine, Catholic University of Paraná, Curitiba, PR; ⁹Department of Community Health, Federal University of Paraná, Curitiba, PR; ¹⁰Department of Pharmacy and Biochemistry, State University of Ponta Grossa, Ponta Grossa, PR; ¹¹Post-Graduate Program in Clinical Surgery, Federal University of Paraná, Curitiba, PR; ¹²Post-Graduate Program in Internal Medicine, Federal University of Paraná, Curitiba, PR, Brazil.

ABSTRACT - Background: Animal models are useful to evaluate the efficacy of antimicrobials in experimental sepsis. **Aim:** To elucidate the steps of producing an experimental model for the treatment of extended-spectrum beta-lactamase (ESBL)-producing *Klebsiella pneumoniae* sepsis. **Methods:** Several ESBL inoculums ranging from 1.5×10^9 colony-forming units per milliliter (CFU/mL) to 2.0×10^{10} CFU/mL were administered by peritoneal injection in adults Wistar rats. Outcomes and microbiological data of quantitative peritoneal and blood cultures were observed in untreated animals. Animals which received 2.0×10^{10} CFU/mL inoculums were treated with single meropenem dose (30mg/kg) after one hour and those which received 1.0×10^{10} CFU/mL inoculums were treated immediately with three doses of meropenem 50 mg/kg. Outcomes were observed for 24 hours after inoculation. **Results:** Solutions with 1.5×10^9 and 6.0×10^9 CFU/mL were not lethal within 24 hours. Inoculums of 1.0×10^{10} CFU/mL were lethal in 80% and solutions with 2.0×10^{10} CFU/mL were lethal in 100% of animals. ESBL lethal sepsis (1.0×10^{10} CFU/mL) was treated immediately with 50 mg/kg of meropenem every eight hours for 24 hours and presented 40% mortality compared with 80% mortality of the control group ($p=0.033$). Quantitative cultures of peritoneal fluid presented 10^4 CFU/mL or less for treated animals compared to more than 10^5 for untreated animals ($p=0.001$). **Conclusion:** Inoculums of 1.0×10^{10} CFU/mL achieved the best results to study a model of lethal sepsis and this model of treatment of carbapenem-susceptible *Enterobacteriaceae* can serve as control to further evaluation of treatment of carbapenemase-producing *Enterobacteriaceae* models.

HEADINGS - *Klebsiella pneumoniae*. Sepsis. Models, animal.

Correspondence:

Paula Toledo
Email: paulavmtoledo@yahoo.com.br

Financial source: CAPES.
Conflicts of interest: none

Received for publication: 30/01/2014
Accepted for publication: 13/05/2014

DESCRITORES - *Klebsiella pneumoniae*.
Sepse. Modelos animais.

RESUMO – Racional: Modelos animais são importantes para avaliar a eficácia de antimicrobianos e a validação do sítio de infecção e a carga bacteriana. **Objetivo:** Definir a concentração do inóculo bacteriano, a dose e o tempo de administração de antimicrobianos a fim de validar um modelo experimental para o tratamento de *Klebsiella pneumoniae* produtora de betalactamase de amplo espectro em sepse letal. **Método:** Inóculos de *Klebsiella pneumoniae* produtora de betalactamase de espectro estendido de $1,5 \times 10^9$ unidades formadoras de colônias por mililitro (UFC/ml) a $2,0 \times 10^{10}$ UFC/ml foram administrados via injeção peritoneal em ratos Wistar adultos. Sobrevida e dados microbiológicos de hemoculturas e culturas quantitativas de fluido peritoneal foram avaliados inicialmente em animais não tratados. Animais inoculados com $2,0 \times 10^{10}$ UFC/ml foram tratados dose única de meropenem (30mg/kg) e animais inoculados com $1,0 \times 10^{10}$ UFC/ml foram tratados imediatamente com meropenem (50 mg/kg) por 24 horas e os desfechos foram avaliados após 24 horas da inoculação. **Resultados:** Soluções com $1,5 \times 10^9$ e $6,0 \times 10^9$ UFC/ml não foram letais. Inóculos de $1,0 \times 10^{10}$ UFC/ml e de $2,0 \times 10^{10}$ UFC/ml foram letais em 80% e 100% dos animais respectivamente. Sepse letal ($1,0 \times 10^{10}$ CFU/mL) com tratamento imediato e por 24 horas apresentou 40% de mortalidade, comparada com 80% nos controles ($p=0.033$). Culturas quantitativas de fluido peritoneal apresentaram $\leq 10^4$ UFC/ml enquanto que controles sem tratamento apresentaram $>10^5$ UFC/ml ($p=0.001$). **Conclusão:** Modelo experimental com inóculo de $1,0 \times 10^{10}$ UFC/ml submetido ao tratamento imediato e por 24 horas foi capaz de avaliar resposta microbiológica e de sobrevida podendo ser modelo de embasamento e de controle para tratamento de sepse letal por *Klebsiella pneumoniae* produtora de carbapenemase.

INTRODUCTION

The incidence of carbapenemase-producing *Enterobacteriaceae* has increased and the ideal treatment has not been established. Some retrospective studies suggest an association of different drugs to improve outcomes^{10,11,12}. Antibiotic therapy to specific bacteria can be evaluated based on global mortality, time to death and rate of microbiological cure. Considering these findings, an experimental model might be helpful to evaluate the combination of different drugs to treat carbapenemase-producing *Enterobacteriaceae* until clinical studies confirm the benefits of this approach. To study animal models on carbapenemase-producing *Enterobacteriaceae*, a treatment control of extended-spectrum betalactamase (ESBL)-producing *Klebsiella pneumoniae* must be validated.

Several animal models of peritonitis, pneumonia and thigh infection after immunosuppression using *Enterobacteriaceae* were reviewed, but none defines a peritonitis

model of ESBL-producing *Klebsiella pneumoniae* treatment with meropenem. Models of peritonitis in rats evaluated inoculums ranging from 10^5 to 10^{10} colony-forming unit per milliliter (CFU/mL) of *E. coli*. Lethal sepsis was observed at higher inoculum concentrations (10^9 to 10^{10} CFU/mL)^{2,3,5}. Non-lethal models were done with 10^5 to 10^8 CFU/mL inoculums^{1,13}. *Klebsiella pneumoniae* was evaluated in peritonitis of neutropenic mice (3×10^5 CFU/mL)⁴, thigh infection in neutropenic rats (10^6 to 10^8 CFU/mL)^{6,8} and pneumonia models in rats (10^6 to 10^{10} CFU/mL)⁷. *Enterobacter* spp. was also evaluated in a pneumonia model of 10^{10} CFU/mL⁹.

Klebsiella pneumoniae inoculum concentrations must be standardized to determine a sepsis model that might be able to evaluate the efficacy of antimicrobial therapy in preventing lethality serving as a control for treatment of carbapenem-resistant *Klebsiella pneumoniae*.

This study aims to describe the more adequate inoculum concentration to induce lethal but treatable sepsis. Timing and dose of antimicrobial therapy for ESBL peritoneal sepsis induced in non-neutropenic rats were evaluated.

METHODS

Animals

The experiment was performed with adult (20–24 week old) male and female Wistar rats weighting 200–340 g. Animals were maintained under artificial day-night cycles, adequate temperature (22–24 °C) and humidity. The rats received a standard diet and water ad libitum. Animals were allowed to adapt to laboratory conditions for two days. The animal research ethics committee of the Universidade Estadual de Ponta Grossa approved the study. Fifty rats were included in the phases of this experiment.

Bacterial strain, inoculum production and sepsis induction

ESBL-producing strain (ATCC 700603) was inoculated into Mueller-Hinton broth and incubated at 37° C for 24 h. Colonies were suspended in sterile isotonic saline solution to form the inoculums.

To accurately measure the inoculum a densimeter (Densimat Biomerieux®) capable of measuring densities of 0.5 to 7.5 McFarland was used to evaluate the inoculums of 1.5×10^9 CFU/mL which was obtained at 5 McFarland. To accurately measure more concentrated inoculums, spectrophotometry (Lambda 25 UV/Vis Spectrophotometer Perkin Elmer®) was performed at optic density of 625 nm. Inoculums with 1.5×10^{10} and 2.0×10^{10} CFU/mL corresponded to solutions of barium chloride and sulfuric acid of 50 and 67 McFarland standards and the absorbencies of these solutions were 2.343 and 2.764 respectively. According to Beer-Lambert law, absorbencies over 0.890 are not accurate for measuring microorganism counts. After 1:20 dilution, inoculums with 1.5×10^{10} and 2.0×10^{10} CFU/mL presented absorbencies of 0.543 and 0.633. Inoculums of 6.0×10^9 CFU/mL and 1×10^{10} were obtained by injection of 0.4 mL and 0.6 mL of 1.5×10^{10} CFU/mL solution.

All inoculums were incubated at Mueller-Hinton and CFU were counted eight hours latter to confirm the concentration before animal injection.

Sepsis was induced by intra-peritoneal injection of the inoculum using a 26 gauge needle in the lower right abdomen. All the procedure was performed under aseptic conditions.

Inoculum lethality was defined by injection of 1.5×10^9 CFU/mL solution in six animals, 6.0×10^9 CFU/mL in five, 1.0×10^{10} CFU/mL in ten animals and 2.0×10^{10} CFU/mL in ten animals.

Antimicrobial therapy

Two groups of ESBL lethal sepsis were treated with meropenem (Astra-Zeneca®). Twelve rats were inoculated

with 2.0×10^{10} CFU/mL and six of them were treated with one dose of meropenem 30 mg/kg after one hour of inoculation. Twenty animals were inoculated with 1.0×10^{10} CFU/mL and ten were treated immediately with 50 mg/kg of meropenem every eight hours for 24 hours. Homogeneous distribution of animals by weight and sex were done in treated and untreated groups.

Outcome evaluation

The rate of lethality, length of survival, blood cultures positivity and quantitative peritoneal fluid and peritoneal tissue cultures were evaluated. Cultures were obtained aseptically.

Animals not presenting lethal sepsis after 24 h suffered euthanasia with lethal doses of xylazine and ketamine.

Blood cultures (0.5–1.0 mL) were collected through cardiac puncture after death or euthanasia and incubated in brain heart infusion broth.

Peritoneal fluid was obtained after laparotomy and injection of 5 mL of isotonic saline and aspiration. One microliter of this fluid was cultured in McConkey agar. Quantitative cultures were performed after 1:100 dilutions of the peritoneal solution in isotonic saline and incubation of 1 µL in McConkey agar.

Statistical analysis

Continuous data were expressed as mean ± standard deviation (SD), frequencies were expressed as percentages. Dichotomous variables were compared using Mann-Whitney test. Kruskal-Wallis test was used to evaluate hours of survival of the four untreated groups. Significance level was set at 0.05. All data were stored using the software Excel (Microsoft, New York, USA) and statistical analysis was performed using the software SPSS 16 (SPSS, Chicago, USA). Graphics and statistical analysis by Mann-Whitney were performed with GraphPad Prism 5.0 (GraphPad, La Jolla, USA).

RESULTS

ESBL solutions ranging from 1.5×10^9 to 2.0×10^{10} CFU/mL were evaluated. Solutions with 1.5×10^9 CFU/mL were not lethal in 100% of animals. Inoculums of 6.0×10^9 and 1.0×10^{10} CFU/mL were lethal in 80% rats. Solutions with 2.0×10^{10} CFU/mL were lethal in 100% of animals (Figure 1). ESBL lethal sepsis (2.0×10^{10} CFU/mL) was treated with meropenem one dose of 30 mg/kg after one hour of inoculation with no improvement on mortality. Other group of ESBL lethal sepsis (1.0×10^{10} CFU/mL) was treated immediately with 50 mg/kg of meropenem every eight hours for 24 hours presented 40% mortality, significantly lower than 80% mortality of the control group ($p=0.042$, Figure 2). Quantitative cultures of peritoneal fluid presented 10^4 CFU/mL or less for treated animals compared to more than 10^5 for untreated animals ($p=0.001$, Figure 3)

DISCUSSION

Previous studies described models of peritoneal inoculums of *E. coli* between 10^5 and 10^{10} CFU/mL to achieve lethal and non-lethal sepsis^{2,5,13}. Recent models of neutropenic rats with thigh infection are performed with lower concentrated inoculums and usually do not evaluate mortality, only microbiologic efficacy⁸. Models with *Klebsiella* spp. are less frequent and must be validated. Here is described the standardization of a lethal model of peritonitis by ESBL-producing *K. pneumoniae* passible of treatment in non immunosuppressed rats.




FIGURE 1 – Survival time in hours of untreated animals according to inoculum concentrations (CFU/ml)




FIGURE 2 – Survival after 1.0x10¹⁰ CFU/mL inoculum in untreated animals and treated immediately with higher meropenem dose




FIGURE 3 – Quantitative peritoneal cultures after treatment of peritonitis. 2.0x10¹⁰ CFU/mL inoculum treated with lower meropenem single dose vs 1.0x10¹⁰ CFU/mL inoculum treated immediately with higher meropenem dose

Solutions of 10⁸ and 10⁹ UFC/mL cause non-lethal

sepsis in immunocompetent rats, which are useful to stratify antimicrobial dosing and compare antimicrobial efficacy on microbiological results, but are not ideal to compare antimicrobial efficacy on clinical outcomes. Was observed that a single antimicrobial dose after inoculation might not be adequate to differentiate treated and untreated animals. Furthermore, was also observed that inoculation of 2.0x10¹⁰ CFU/mL with no immediate treatment, cause lethal sepsis that may not be adequate to evaluate antimicrobial efficacy on survival, since most animals may die in spite of treatment.

Inoculums of more than 1.0x10¹⁰ and less than 2.0x10¹⁰ colony-forming units per milliliter, accurately measured by spectrophotometry, produce lethal sepsis. Immediate treatment after inoculation, administered for 24 hours permits to compared outcomes and microbiological samples of treated and untreated animals. The immediate antimicrobial infusion was based on previous studies^{2,5}. Was thought that immediate infusion of antibiotic could reduce the bacterial burden, but both groups had positive cultures in the end of the experiment.

This study validates an animal model of sepsis which induced lethal peritonitis in the control group between six and 24 hours and the treated group had cultures with significantly fewer microorganisms. Data from quantitative cultures, length of survival and mortality can serve as a control to evaluate the treatment of carbapenemase-producing *Enterobacteriaceae* models.

CONCLUSION

Inoculums of 1.0x10¹⁰CFU/mL achieved the best results to study a model of lethal sepsis and this model of treatment of carbapenem-susceptible *Enterobacteriaceae* can serve as control to further evaluation of treatment of carbapenemase-producing *Enterobacteriaceae* models.

ACKNOWLEDGMENTS

We would like to thank the Animal Laboratory staff.

REFERENCES

- Bosscha K, Nieuwenhuijs VB, Gooszen AW, van Duijvenbode-Beumer H, Visser MR, Verweij WR, Akkermans L M. A standardised and reproducible model of intraabdominal infection and abscess formation in rats. *Eur J Surg* 2000; 166: 963-967.
- Cirioni O, Giacometti A, Ghiselli R, Mocchegiani F, Fineo A, Orlando F, Del Prete MS, Rocchi M, Saba V, Scalise G. Single-dose intraperitoneal magainins improve survival in a gram-negative-pathogen septic shock rat model. *Antimicrob Agents Chemother* 2002; 46: 101-104.
- Davis SD. Activity of gentamicin, tobramycin, polymyxin B, and colistimethate in mouse protection tests with *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 1975; 8: 50-53.
- Endimiani A, Hujer KM, Hujer AM, Pulse ME, Weiss WJ, Bonomo RA. Evaluation of ceftazidime and NX104 in two murine models of infection due to KPC-producing *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 2011; 55: 82-85.
- Giacometti A, Cirioni O, Ghiselli R, Mocchegiani F, Paggi AM, Orlando F, Kamysz W, Kasprzykowski F, Mackiewicz Z, Scalise G, Saba V. Therapeutic efficacy of intraperitoneal polymyxin B and polymyxin-like peptides alone or combined with levofloxacin in rat models of septic shock. *J Antimicrob Chemother* 2002; 49: 193-196.
- Housman ST, Keel RA, Crandon JL, Williams G, Nicolau DP. Efficacy of human simulated exposures of ceftaroline against phenotypically diverse *Enterobacteriaceae* isolates. *Antimicrob Agents Chemother* 2012; 56: 2576-2580.
- Kesteman AS, Ferran AA, Perrin-Guyomard A, Laurentie M, Sanders P, Toutain PL, Bousquet-Mélou A. Influence of inoculum size and marbofloxacin plasma exposure on the amplification of resistant subpopulations of *Klebsiella pneumoniae* in a rat lung infection model. *Antimicrob Agents Chemother* 2009; 53: 4740-4748.

8. Maglio D, Banevicius MA, Sutherland C, Babalola C, Nightingale CH, Nicolau DP. Pharmacodynamic profile of ertapenem against *Klebsiella pneumoniae* and *Escherichia coli* in a murine thigh model. *Antimicrob Agents Chemother* 2005; 49: 276-280.
9. Mimos O, Leotard S, Jacolot A, Padoin C, Louchahi K, Petitjean O, Nordmann P. Efficacies of imipenem, meropenem, cefepime, and ceftazidime in rats with experimental pneumonia due to a carbapenem-hydrolyzing beta-lactamase-producing strain of *Enterobacter cloacae*. *Antimicrob Agents Chemother* 2000; 44: 885-890.
10. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, Polsky B, Adams-Haduch JM, Doi Y. Treatment outcome of bacteremia due to KPC-producing *Klebsiella pneumoniae*: superiority of combination antimicrobial regimens. *Antimicrob Agents Chemother* 2012; 56: 2108-2113.
11. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M. Predictors of mortality in bloodstream infections caused by *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae*: importance of combination therapy. *Clin Infect Dis* 2012; 55: 943-950.
12. Tuon FF1, Rocha JL, Toledo P, Arend LN, Dias CH, Leite TM, Penteado-Filho SR, Pilonetto M, Zavascki AP. Risk factors for KPC-producing *Klebsiella pneumoniae* bacteremia. *Braz J Infect Dis* 2012; 16: 416-419.
13. Wandall DA, Arpi M, Wandall JH. A rat model of non-lethal bacterial infection. *APMIS* 1997; 105: 187-191.